Fractyl Health, Inc.
GUTSFractyl Health, Inc. in brief
Fractyl Health, Inc. is a listed company in the Healthcare sector, based in Burlington, Massachusetts, USA. Its market value was $13 M on 30 October 2026, which makes it the 25,361st largest listed company in the world and the 4,237th largest in the USA on this site. It employs about 100 people and Harith Rajagopalan is its chief executive. Its shares trade under the symbol GUTS (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Fractyl Health, Inc.
We are a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes. Our Revita® and Rejuva® candidates are designed to target root causes of metabolic diseases, allowing us to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease.
Despite advances in treatment over the last 50 years, obesity and T2D continue to be principal and rapidly growing drivers of morbidity and mortality. According to the Centers for Disease Control approximately 115 million people in the U.S. have prediabetes and/or are living with obesity, and an additional approximately 27 million people have T2D and are potentially on medical therapy. Within the past two years, the unmet need in obesity has shifted rapidly from identifying treatments that can achieve short-term weight loss to identifying treatments that can enable durable weight maintenance. While highly potent drugs in the glucagon-like peptide-1 receptor agonist class are now available to lower weight and blood sugar, these agents have high discontinuation rates that lead to a substantial risk of weight and metabolic rebound. According to a Kaiser Family Foundation Health Tracking Poll from November 2025, approximately 12% of adults are taking glucagon-like peptide-1 drugs (an increase of 6 percentage points from May 2024), translating to approximately 30 million patients potentially on therapies that require chronic administration and do not correct the underlying disease of obesity. Despite the growing interest in these drugs, a Blue Health Intelligence brief from 2024 found that over 50% of patients discontinue GLP-1 drugs within three months of starting, long before patients can experience clinical benefit from these agents.
From the company's annual report filed with the US SEC: read the report
Fractyl Health, Inc. timeline
- 2013
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2020
- ✎Renamed Fractyl Health, Inc.Formerly Fractyl Laboratories Inc..
- 2024
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 2 February 2024; shares registered for exchange trading on 29 January 2024.
Events of Fractyl Health, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,390 (Aug 2026) · #3,771 (Oct 2026) · #4,239 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 1.4×
- Free cash flow yield
- -692.2%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -1490.0%
- Liabilities / assets
- 92.2%
- Revenue growth
- -25.0%
- R&D / revenue
- 78300.0%
- Profit per employee
- $-1.4 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-97M | $-141M | — |
| Dec 2024 | $0M | -25.0% | $-94M | $-69M | -76322.2% |
| Dec 2023 | $0M | — | $-51M | $-77M | -64241.7% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-90M | $1M | $-91M | $-1.86 | — |
| Dec 2024 | $-66M | $2M | $-67M | $-1.62 | — |
| Dec 2023 | $-43M | $0M | $-43M | $-45.29 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-14M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Nov 6, 20268-KCurrent reportDirectors or officers changed
- Oct 22, 20268-KCurrent reportRestructuring costs · Directors or officers changed · Other events
- Oct 16, 20268-KCurrent reportRegulation FD disclosure · Other events
- Oct 1, 20268-KCurrent reportBylaws amended
- Sep 24, 20268-KCurrent reportShareholder vote
- Sep 11, 20268-KCurrent reportListing notice
- Aug 24, 2026DEF 14AProxy statement
- Aug 10, 202610-QQuarterly report · period to Jun 2026
- Aug 10, 20268-KCurrent reportResults of operations
- Jul 15, 20268-KCurrent reportRegulation FD disclosure · Other events
Official filings of Fractyl Health, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-97 M
- Net income
- $-141 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $121 M
- Total liabilities
- $112 M
- Total equity
- $9 M
As of December-2025
Top 6 institutional investors in Fractyl Health, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Nantahala Capital Management, LLC | 7,458,269 | New | 56.23% | $4 M | Nov 13, 2026 |
| 2 | Marshall Wace, LLP | 1,884,135 | New | 14.20% | $1 M | Nov 13, 2026 |
| 3 | Parallel Advisors, LLC | 47,835 | New | 0.36% | $0 M | Nov 3, 2026 |
| 4 | FNY Investment Advisers, LLC | 35,600 | New | 0.27% | $0 M | Oct 16, 2026 |
| 5 | Catalyst Funds Management Pty Ltd | 10,831 | New | 0.08% | $0 M | Nov 12, 2026 |
| 6 | SBI Securities Co., Ltd. | 4,021 | New | 0.03% | $0 M | Oct 22, 2026 |
Mutual funds holding Fractyl Health, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 4.62 M | $4 M | 2.9% | <0.01% | +12% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 1.25 M | $1 M | 0.79% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 594,704 | $0 M | 0.38% | <0.01% | +13% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 214,366 | $0 M | 0.14% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 181,077 | $0 M | 0.12% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 149,625 | $0 M | 0.10% | <0.01% | +945% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 104,682 | $0 M | 0.07% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 71,631 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 67,750 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 15,009 | $0 M | <0.01% | <0.01% | +18% | Jul 31, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 10,500 | $0 M | <0.01% | <0.01% | −3.7% | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 3,247 | $0 M | <0.01% | <0.01% | +33% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 12 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Fractyl Health, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | William BradleyDirector | Buy | +64,516 | $0.620 | $40 K | 149,138 | Form 4 |
| filed | Ajay RoyanDirector | Buy | +23,000 | $0.850 | $20 K | 40,901 | Form 4 |
| filed | William BradleyDirector | Buy | +68,493 | $0.730 | $50 K | 84,622 | Form 4 |
| filed | Harith RajagopalanChief Executive Officer, Director | Buy | +25,000 | $0.730 | $18 K | 540,557 | Form 4 |
| filed | Ian SheffieldDirector | Buy | +35,000 | $0.730 | $26 K | 35,000 | Form 4 |
| filed | Weber Lara SmithChief Financial Officer | Buy | +20,000 | $0.690 | $14 K | 20,000 | Form 4 |
| filed | Harith RajagopalanChief Executive Officer, Director | Buy | +10,416 | $1.920 | $20 K | 501,745 | Form 4 |
| filed | Ajay RoyanDirector, 10% owner | Buy | +17,901 | $1.280 | $23 K | 17,901 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Fractyl Health, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 12-for-1 split ; 1-for-2.15 reverse split
Trading halts
- 2026-10-02 23:50 UTC, code T3, resumed 13:00 UTC
Fails to deliver
- : 30,589 shares at $0.99
- : 69 shares at $1.33
- : 84 shares at $1.55
- : 122 shares at $4.08
- : 83 shares at $4.41
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Fractyl Health, Inc. scorecard#
Passes 2 of the 9 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.
Valuation1 of 3
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.4×Price to book 1.4× against Healthcare's median of 3.1×.
- –Price to sales below its peers' medianNo Price to sales on file.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.86 vs -1.62Diluted EPS -1.86 in fiscal 2025 against -1.62 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$141 MNet income -$141 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-744.2%-744.2% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities4.8×Current ratio 4.78 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year74.1%Diluted shares up 74.1% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Fractyl Health, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 0−100%— | 0.1−22.5%100% | 0.1—100% | |
| Cost of revenue | 0−100%— | 0.1−35.1%53.8% | 0.1—64.2% | |
| Gross profit | — | 0.00.0%46.2% | 0.0—35.8% | |
| Research and development | 75+5.8%— | 70+85.3%75775% | 38—31698% | |
| Selling, general and administrative | 22−3.6%— | 23+79.9%24842% | 13—10701% | |
| Operating expenses | 97+3.5%— | 94+83.9%100617% | 51—42399% | |
| Operating income | −97—— | −94—−100571% | −51—−42363% | |
| Interest and finance income | 1.5−62.9%— | 4.1+229%4458% | 1.3—1050% | |
| Other non-operating income (expense) | −44−278%— | 25—26706% | −26—−21879% | |
| Income tax | 0—— | 0—0.0% | 0—0.0% | |
| Net income including minority interests | −141—— | −69—−73865% | −77—−64242% | |
| Net income attributable to shareholders | −141—— | −69—−73865% | −77—−64242% | |
| Earnings per share, basic | -1.86—— | -1.62—— | -45.29—— | |
| Earnings per share, diluted | -1.86—— | -1.62—— | -45.29—— | |
| Shares, weighted average (basic) | 76+74.1%— | 44+1992%— | 2.1—— | |
| Shares, weighted average (diluted) | 76+74.1%— | 44+1992%— | 2.1—— | |
| Balance sheet | ||||
| Cash and cash equivalents | 82+20.9%67.2% | 67+103%62.4% | 33—43.6% | |
| Receivables | — | 0−100%0.0% | 0.0—0.0% | |
| Inventory | — | 0.10.0%0.1% | 0.1—0.1% | |
| Other current assets | 6.0—5.0% | — | — | |
| Current assets | 88+22.0%72.1% | 72+101%66.4% | 36—46.8% | |
| Property, plant and equipment | 2.4−19.2%2.0% | 3.0+508%2.8% | 0.5—0.6% | |
| Right-of-use (leased) assets | 27−5.6%22.1% | 28−6.2%26.3% | 30—39.7% | |
| Total assets | 121+12.3%100% | 108+41.8%100% | 76—100% | |
| Accounts payable | 1.6−51.4%1.3% | 3.2+486%3.0% | 0.6—0.7% | |
| Current liabilities | 18−7.3%15.1% | 20+76.8%18.3% | 11—14.7% | |
| Lease liabilities (non-current) | 26−5.2%21.4% | 27−3.9%25.3% | 29—37.4% | |
| Total liabilities | 112+40.5%92.2% | 80−30.1%73.7% | 114—150% | |
| Retained earnings | −556—−458% | −415—−384% | −347—−455% | |
| Shareholders' equity | 9.5−66.7%7.8% | 28—26.3% | −325—−427% | |
| Total liabilities and equity | 121+12.3%100% | 108+41.8%100% | 76—100% | |
| Shares outstanding | 13r153−73.8%— | 49+2215%— | 2.1—— | |
| Cash-flow statement | ||||
| Share-based compensation | 6.7−53.7%— | 14+236%15512% | 4.3—3580% | |
| Cash from operating activities | −90—— | −66—−70453% | −43—−35686% | |
| Capital expenditure | −0.6—— | −1.8—−1898% | −0.4—−299% | |
| Cash from investing activities | −0.6—— | −1.8—−1898% | −0.4—−299% | |
| Shares issued | 6.8—— | — | — | |
| Cash from financing activities | 105+3.7%— | 101+269%108845% | 27—22864% | |
| Change in cash | 14−58.5%— | 34—36495% | −16—−13121% | |
| Report | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||||
| Revenue | — | — | — | — | — | — | — | — | 0.0*—100% | 0.0—100% | 0.0—100% | 0.0—100% | |
| Cost of revenue | — | — | — | — | — | — | — | — | 0*—0.0% | 0.0—50.0% | 0.0—55.8% | 0.0—57.6% | |
| Gross profit | — | — | — | — | — | — | — | — | 0.0*—100% | 0.0—50.0% | 0.0—44.2% | 0.0—42.4% | |
| Research and development | 58−25.5%— | 12−28.7%— | 14−34.7%— | 16−19.7%— | 16*−18.7%— | 17−8.1%— | 21+26.2%— | 19+34.7%— | 20*—676033% | 19—135743% | 17—38981% | 14—43709% | |
| Selling, general and administrative | 23+15.0%— | 6.2+18.3%— | 5.3+7.2%— | 5.2−1.9%— | 6.8*+37.7%— | 5.2+9.2%— | 4.9−21.1%— | 5.3−25.4%— | 4.9*—164400% | 4.8—34264% | 6.2—14516% | 7.1—21612% | |
| Operating expenses | 82−17.1%— | 19−17.8%— | 19−26.8%— | 21−15.9%— | 23*−7.7%— | 23−4.7%— | 26+13.4%— | 25+14.9%— | 25*—840433% | 24—170007% | 23—53498% | 22—65321% | |
| Operating income | −82—— | −19—— | −19—— | −21—— | −23*—— | −23—— | −26—— | −25—— | −25*—−840333% | −24—−169957% | −23—−53453% | −22—−65279% | |
| Interest and finance income | 2.0+21.3%— | 0.3+78.9%— | 0.4+90.7%— | 0.6+17.9%— | 0.6*−11.2%— | 0.2−82.5%— | 0.2−83.6%— | 0.5−54.2%— | 0.7*—24200% | 0.9—6764% | 1.4—3198% | 1.1—3327% | |
| Other non-operating income (expense) | 7.7—— | 4.5—— | −6.4—— | 30+2833%— | −20*−8618%— | −23−3789%— | −1.8−131%— | 1.0−94.4%— | 0.2*—8000% | 0.6—4436% | 5.8—13386% | 18—55212% | |
| Net income including minority interests | −74—— | −14*—— | −26*—— | 9.2—— | −44*—— | −46*—— | −28*—— | −24—— | −25*—−832333% | −23*—−165521% | −17*—−40067% | −3.3—−10067% | |
| Net income attributable to shareholders | −74—— | −14—— | −26—— | 9.2—— | −44*—— | −46—— | −28—— | −24—— | −25*—−832333% | −23—−165521% | −17—−40067% | −3.3—−10067% | |
| Earnings per share, basic | — | -1.07—— | -0.16—— | 0.06—— | — | -8.46r-0.71—— | -0.57—— | -0.49—— | — | -0.48—— | -0.36—— | -0.17—— | |
| Earnings per share, diluted | — | -1.07—— | -0.16—— | 0.06—— | — | -8.46r-0.71—— | -0.57—— | -0.49—— | — | -0.48—— | -0.36—— | -0.17—— | |
| Shares, weighted average (basic) | 13+146%— | 13+146%— | 159+223%— | 158+224%— | — | 5.4r65−88.8%— | 49+2.4%— | 49+64.3%— | — | 48—— | 48—— | 30—— | |
| Shares, weighted average (diluted) | 13+146%— | 13+146%— | 159+223%— | 158+224%— | — | 5.4r65−88.8%— | 49+2.4%— | 49+64.3%— | — | 48—— | 48—— | 30—— | |
| Balance sheet | |||||||||||||
| Cash and cash equivalents | 32—47.8% | 32−59.4%47.8% | 47+111%57.5% | 63+50.0%63.6% | 82+20.9%67.2% | 78−8.3%68.0% | 22−78.2%35.9% | 42−65.3%50.7% | 67—62.4% | 85—66.7% | 102—70.0% | 121—74.3% | |
| Receivables | — | — | — | — | — | — | — | — | 0—0.0% | 0—0.0% | 0.0—0.0% | 0.0—0.0% | |
| Inventory | — | — | — | — | — | — | — | — | 0.1—0.1% | 0.1—0.1% | 0.1—0.0% | 0.1—0.0% | |
| Other current assets | 2.8—4.3% | 2.8—4.3% | 2.5—3.0% | — | 6.0—5.0% | — | — | — | — | — | — | — | |
| Current assets | 34—52.1% | 34−56.9%52.1% | 50+85.9%60.5% | 66+40.1%66.3% | 88+22.0%72.1% | 80−9.1%69.7% | 27−75.0%43.0% | 47−62.2%56.7% | 72—66.4% | 88—69.1% | 107—72.8% | 124—76.1% | |
| Property, plant and equipment | 1.7—2.6% | 1.7−37.2%2.6% | 1.8−37.7%2.3% | 2.1−32.2%2.1% | 2.4−19.2%2.0% | 2.7−10.6%2.3% | 3.0−6.5%4.8% | 3.1+64.9%3.8% | 3.0—2.8% | 3.0—2.4% | 3.2—2.2% | 1.9—1.2% | |
| Right-of-use (leased) assets | 26—38.7% | 26−6.3%38.7% | 26−6.1%31.7% | 26−5.8%26.6% | 27−5.6%22.1% | 27−5.4%23.8% | 28−5.2%44.6% | 28−5.3%33.8% | 28—26.3% | 29—22.7% | 29—19.9% | 30—18.1% | |
| Total assets | 66—100% | 66−42.3%100% | 82+32.2%100% | 99+19.7%100% | 121+12.3%100% | 114−10.0%100% | 62−57.7%100% | 83−49.2%100% | 108—100% | 127—100% | 146—100% | 164—100% | |
| Accounts payable | 1.7—2.6% | 1.7+36.8%2.6% | 1.0−74.3%1.2% | 1.6+11.5%1.7% | 1.6−51.4%1.3% | 1.3−28.6%1.1% | 3.9+71.0%6.3% | 1.5+44.0%1.8% | 3.2—3.0% | 1.8—1.4% | 2.3—1.6% | 1.0—0.6% | |
| Current liabilities | 17—26.3% | 17−7.2%26.3% | 16−27.9%19.2% | 15−18.0%15.5% | 18−7.3%15.1% | 19+18.9%16.3% | 22+52.9%35.2% | 19+41.7%22.6% | 20—18.3% | 16—12.4% | 14—9.8% | 13—8.1% | |
| Lease liabilities (non-current) | 25—37.4% | 25−6.4%37.4% | 25−6.0%30.6% | 26−5.6%25.7% | 26−5.2%21.4% | 26−4.9%23.1% | 27−4.5%43.1% | 27−4.2%32.6% | 27—25.3% | 28—21.8% | 28—19.1% | 28—17.3% | |
| Total liabilities | 79—120% | 79−32.6%120% | 84+4.3%102% | 78+1.8%78.5% | 112+40.5%92.2% | 117+53.3%103% | 80+6.0%129% | 77−3.4%92.3% | 80—73.7% | 77—60.4% | 76—51.7% | 79—48.5% | |
| Retained earnings | −587—−890% | −587—−890% | −573—−698% | −547—−550% | −556—−458% | −513—−449% | −467—−753% | −439—−529% | −415—−384% | −390—−308% | −367—−251% | −350—−214% | |
| Shareholders' equity | −13—−20.0% | −13—−20.0% | −1.7—−2.0% | 21+235%21.5% | 9.5−66.7%7.8% | −3.2−106%−2.8% | −18−126%−29.4% | 6.4−92.4%7.7% | 28—26.3% | 50—39.6% | 71—48.3% | 84—51.5% | |
| Total liabilities and equity | 66—100% | 66−42.3%100% | 82+32.2%100% | 99+19.7%100% | 121+12.3%100% | 114−10.0%100% | 62−57.7%100% | 83−49.2%100% | 108—100% | 127—100% | 146—100% | 164—100% | |
| Shares outstanding | 13—— | 13−90.0%— | 159+218%— | 159+224%— | 13r153−73.8%— | 132+175%— | 50+4.2%— | 49+2.1%— | 49—— | 48—— | 48—— | 48—— | |
| Cash-flow statement | |||||||||||||
| Share-based compensation | 9.3+19.9%— | 2.4+45.7%— | 2.5+39.8%— | 2.5+80.0%— | 1.9*−36.0%— | 1.6−35.0%— | 1.8−52.9%— | 1.4−73.0%— | 2.9*—96633% | 2.5—18000% | 3.8—8814% | 5.2—15809% | |
| Cash from operating activities | −75—— | −16*—— | −16*—— | −22—— | −21*—— | −23*—— | −21*—— | −25—— | −17*—−567800% | −18*—−128850% | −19*—−43574% | −12—−35488% | |
| Capital expenditure | — | — | — | — | −0.0*—— | −0.0*—— | −0.1*—— | −0.4—— | −0.2*—−7767% | −0.2*—−1521% | −0.3*—−605% | −1.1—−3209% | |
| Cash from investing activities | — | — | — | — | −0.0*—— | −0.0*—— | −0.1*—— | −0.4—— | −0.2*—−7767% | −0.2*—−1521% | −0.3*—−605% | −1.1—−3209% | |
| Shares issued | — | — | — | 0.2—— | 4.7*—— | 0.5*—— | — | — | — | — | — | — | |
| Cash from financing activities | 29−63.3%— | 0.1*−99.9%— | −0.1*−109%— | 4.1+2301%— | 25*+37545%— | 78*+48102%— | 1.5*—— | 0.2−99.8%— | 0.1*—2233% | 0.2*—1157% | −0.0*—−11.6% | 101—306067% | |
| Change in cash | −46—— | −16*−128%— | −16*—— | −18—— | 3.9*—— | 55*—— | −20*—— | −25−129%— | −17*—−573333% | −18*—−129214% | −19*—−44191% | 88—267370% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Fractyl Health, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Delisting notice 2 · Restructuring 1 · Directors and officers 4 · Material agreement 2 · Bylaws or fiscal year changed 1 · Shareholder vote 4 · Results announced 7
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| RestructuringDirectors and officers | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
6 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2021 | $100 M | No. 6 | $50 to $250 million | 15 | equity | SEC |
| Mar 2020 | $45 M | No. 5 | $10 to $50 million | 15 | equity | SEC |
| Jun 2017 | $44 M | No. 4 | $10 to $50 million | 19 | equity | SEC |
| Oct 2015 | $47 M | No. 3 | $10 to $50 million | 16 | equity | SEC |
| Aug 2014 | $20 M | No. 2 | $10 to $50 million | 13 | equity | SEC |
| Mar 2013 | $14 M | No. 1 | $10 to $50 million | 11 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Fractyl Health, Inc.#
1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $143 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Manager, Regulatory AffairsRegulatory Affairs Specialists | 1 | $143 K |
Where: Burlington, MA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 1 | 1 | $143 K | 1 |
| FY2024 | 2 | 2 | $115 K | 2 |
| FY2023 | 1 | 1 | $125 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Fractyl Health, Inc.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | · | · | · | · | · | · | · | · | · | · | · | — | |
| 2025 | 22 | · | · | · | · | · | · | · | · | · | · | · | 22 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 45% of workforce | Restructuring planSEC 8-K | “As part of the plan, the Company will reduce its workforce by approximately 45% of the Company’s current headcount.” | Filing | |
| 22 people (17% of workforce) | Restructuring planSEC 8-K | “As part of the Strategic Reprioritization, the Company is streamlining resources, including a workforce reduction impacting 22 employees, or approximately 17% of the Company’s work…” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Fractyl Health, Inc. compares in Healthcare
- Market cap$13 M · higher than 9% of 2,013
- Revenue growth-25.0% · higher than 16% of 1,003
- Price / book1.4× · lower than 73% of 1,245
Peer comparison · Healthcare
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Fractyl Health, Inc.🇺🇸 | $13 M | — | — | -25.0% |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| UnitedHealth Group Incorporated🇺🇸 | $367.7 B | 23.1× | 3.5% | +11.8% |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of March 1, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, Wikidata, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Fractyl Health, Inc.? Verify and update this profile — free
Show Fractyl Health, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.